Conclusion and Last Remarks
Recommendations
In my opinion, there is a tendency to over-complicate things
We don’t have to complicate things because other platform trials were complicated
Every platform trial is different
Multiple ways to build and maintain an “airport”
Let’s be honest about different trade-offs
The main statistical efficiency comes from multi-arm aspect of platform trial
We need to work in a cross-functional team, and we need to advocate for structural changes
Not easy but not impossible
- Especially not easy the first time, it does get easier (I think?)
References
1. Park JJ, Detry MA, Murthy S, Guyatt G, Mills EJ. How to use and interpret the results of a platform trial: users’ guide to the medical literature. Jama. 2022 Jan 4;327(1):67-74.
2. Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi LO, Sydes MR, Villar SS. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC medicine. 2018 Dec;16(1):1-5
3. Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018 Mar 8;360
4. A Practical Adaptive & Novel Designs and Analysis (PANDAS) toolkit
5. Park JJ, Mills EJ, Wathen JK. Introduction to Adaptive Trial Designs and Master Protocols. Cambridge University Press; 2023 Apr 6
6. ClinicalTrials.Gov for the TOGETHER Trial: NCT04727424
7. Forrest JI et al., Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. The American Journal of Tropical Medicine and Hygiene. 2022 Feb;106(2):389.
Book
